Artiva Biotherapeutics sets 2026 annual meeting date
Artiva Biotherapeutics, Inc. set September 8, 2026 as the expected date for its 2026 annual meeting of stockholders, a date that falls more than 70 days after the one-year anniversary of the 2025 annual meeting.
Rhea-AI Filing Summary
Artiva Biotherapeutics, Inc. set September 8, 2026 as the expected date for its 2026 annual meeting of stockholders, a date that falls more than 70 days after the one-year anniversary of the 2025 annual meeting. The company is an emerging growth company with common stock listed on the Nasdaq Global Market under the symbol ARTV.
Under its amended and restated bylaws and Exchange Act Rule 14a-8, stockholders must deliver notices of any business, director nominations, or proposals for inclusion in the proxy statement to the company's San Diego principal executive offices by the close of business on August 1, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
2026 Annual Meeting date: September 8, 2026
Proposal and nomination deadline: August 1, 2026
Timing difference: more than 70 days
+1 more
4 metrics
2026 Annual Meeting date
September 8, 2026
Expected date for the 2026 annual meeting of stockholders
Proposal and nomination deadline
August 1, 2026
Deadline for stockholder business, director nominations, and Rule 14a-8 proposals
Timing difference
more than 70 days
Meeting date is more than 70 days after the one-year anniversary of the 2025 annual meeting
Principal executive office address
5505 Morehouse Drive, Suite 100
Location for delivery of stockholder notices in San Diego, California 92121
Key Terms
Rule 14a-8, amended and restated bylaws, proxy statement, emerging growth company
4 terms
Rule 14a-8 regulatory
"stockholder proposals intended for inclusion in the Company’s proxy statement for the Annual Meeting pursuant to Rule 14a-8"
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
amended and restated bylaws regulatory
"in accordance with the Company’s amended and restated bylaws (the “Bylaws”)"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
proxy statement regulatory
"stockholder proposals intended for inclusion in the Company’s proxy statement for the Annual Meeting"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
When is Artiva Biotherapeutics (ARTV) holding its 2026 annual meeting?
Artiva Biotherapeutics plans to hold its 2026 annual meeting on September 8, 2026. This date is more than 70 days after the one-year anniversary of the 2025 meeting, which affects timing rules for stockholder business and nomination notices.
What is the deadline for Artiva Biotherapeutics (ARTV) stockholder proposals under Rule 14a-8?
Stockholder proposals for Artiva Biotherapeutics' proxy under Rule 14a-8 are due by August 1, 2026. Proposals must reach the company's principal executive offices by the close of business to be eligible for inclusion in the 2026 annual meeting proxy statement.
By when must ARTV stockholders submit director nominations or other business for the 2026 meeting?
Stockholders must submit any director nominations or other business by the close of business on August 1, 2026. These notices must comply with Artiva's amended and restated bylaws and applicable Exchange Act rules for consideration at the 2026 annual meeting.
Where should Artiva Biotherapeutics (ARTV) stockholders send 2026 meeting proposals or notices?
Stockholders should send proposals and notices to Artiva Biotherapeutics, Inc., Attention: Secretary, 5505 Morehouse Drive, Suite 100, San Diego, California 92121. Delivery to this principal executive office address is required for timely business, nominations, and Rule 14a-8 proposals.
Why did Artiva Biotherapeutics (ARTV) set special deadlines for 2026 stockholder proposals?
Special deadlines apply because the 2026 annual meeting is scheduled for September 8, 2026, more than 70 days after the prior year's anniversary. This timing triggers bylaw provisions that reset when stockholders must submit business, director nominations, and Rule 14a-8 proposals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
